LYRA THERAPEUTICS INC (LYRA)
US55234L1052 - Common Stock
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 --
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology...
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lyra Therapeutics (NASDAQ:LYRA) just reported results for the second quarter of...
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS...
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday!
Monday Sector Laggards: Food, Drugs
DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges
Trump Media & Technology stock is up on Monday as DJT investors react to the company naming a new auditor as its old one faces SEC charges.
ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range?
Zeekr is planning an IPO this week that will have the Chinese EV company pricing shares of ZK stock between $18 and $21 per share.
Warren Buffett Just Gave Up on Paramount (PARA) Stock
Paramount Global stock is on the move Monday after Warren Buffett revealed he sold all of the PARA shares owned by Berkshire Hathaway.
Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today?
Lyra Therapeutics stock is falling hard with heavy trading on Monday after the company reported a failed Phase 3 clinical trial.
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE...
Lyra Therapeutics Shares Cross Below 200 DMA
Lyra Therapeutics Becomes Oversold (LYRA)
LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024
LYRA stock results show that Lyra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lyra Therapeutics (NASDAQ:LYRA) just reported results for the first quarter of ...
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --...
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech...
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lyra Therapeutics (NASDAQ:LYRA) just reported results for the fourth quarter of...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 ...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology...
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided...
Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology...
Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery
Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically...
Lyra Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative...
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
Topline Results Expected 1H 2024...